Global Infectious Disease Therapeutics Market Report 2024

The infectious disease therapeutics market size has grown strongly in recent years. It will grow from $132.14 billion in 2023 to $141.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historic period can be attributed to several factors, including the rising prevalence of infectious diseases, increasing incidence of viral diseases, growing awareness about diagnosis, rising demand for efficient and quick diagnostic testing, growing demand for cost-effective generic drugs, the increasing prevalence of infectious diseases, and the growing importance of antimicrobial stewardship.

The infectious disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $184.17 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the forecast period can be attributed to several factors, including increasing investments, expansion of clinical trial studies, a rising number of clinical trials, a growing focus on infectious disease prevention, increasing awareness about early diagnosis, and growing awareness and funding. Major trends expected in the forecast period include partnerships, product approvals, investments, and research and developments in therapeutics.

The anticipated increase in infectious diseases is poised to drive the growth of the infectious disease therapeutics market in the foreseeable future. Infectious diseases are caused by various pathogenic microorganisms, including bacteria, viruses, fungi, parasites, or prions. Several factors contribute to the rising prevalence of infectious diseases, such as climate change, environmental disruption, antimicrobial resistance, weakened immune systems, increased interactions with animals, and ecological disturbances. Infectious disease therapeutics play a crucial role in treating infections, reducing morbidity and mortality, and controlling the spread of communicable diseases within communities and across populations. For example, according to data from gov.uk, there were 3,805 new HIV diagnoses in England in 2022, marking a 22% increase from the previous year and a 26% rise from 2020. Thus, the increasing prevalence of infectious diseases is a driving force behind the growth of the infectious disease therapeutics market.

Key players in the infectious disease therapeutics market are making strategic investments in infectious disease drugs to develop more effective treatments, combat antimicrobial resistance, expand their product portfolios, and address emerging infectious threats. These investments aim to improve patient outcomes, meet unmet medical needs, and contribute to global public health efforts to control and manage infectious diseases. For instance, in June 2022, GSK, a UK-based healthcare company, announced a £1 billion (USD 1.09 billion) investment to proactively address infectious diseases in lower-income countries. This initiative seeks to enhance research and development efforts to combat diseases that disproportionately affect these regions. The disparity in health research funding and resources between high-income and low- and middle-income countries underscores the urgency for such proactive investments to improve population health equitably.

In May 2022, OPKO Health, a US-based healthcare company, completed the acquisition of Modex Therapeutics for $300 million. This acquisition significantly bolstered OPKO's technology foundation and expanded its product pipeline into new therapeutic areas, particularly oncology and infectious diseases. Modex Therapeutics, a US-based biotechnology company, specializes in manufacturing infectious disease therapeutics.

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.

North America was the largest region in the infectious disease therapeutics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infectious disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Infectious disease therapeutics encompass a range of treatments and interventions designed to combat illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites. The primary goal of infectious disease therapeutics is to either eliminate the infectious agent from the body or to control its replication and spread, thereby alleviating symptoms, preventing complications, and ultimately promoting recovery.

The main types of infectious disease therapeutics include drugs and vaccines. Vaccines are biological preparations that stimulate the immune system to recognize and combat specific infectious agents. These therapeutics are utilized to address various diseases such as tuberculosis, HIV/AIDS, influenza, hepatitis, and others. They are accessed by various end-users including hospitals and clinics, retail pharmacies, research organizations, and others.

The infectious disease therapeutics market research report is one of a series of new reports that provides infectious disease therapeutics market statistics, including infectious disease therapeutics industry global market size, regional shares, competitors with an infectious disease therapeutics market share, detailed infectious disease therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the infectious disease therapeutics industry. This infectious disease therapeutics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The infectious disease therapeutics market consists of sales of antibiotics, antivirals, and immunotherapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.